Orlistat
Based on 34 publication(s) in Google Scholar
Orlistat (Tetrahydrolipstatin) is a well-known irreversible inhibitor of pancreatic and gastric lipases. Orlistat is also an inhibitor of fatty acid synthase (FASN), is used orally for long-term research of obesity. Anti-atherosclerotic effect.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.94%
- No. CAS: 96829-58-2
- Fòrmula: C29H53NO5
- Peso molecular:495.73
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Orlistat
More- Cell Stem Cell. 2025 Dec 4;32(12):1849-1868.e15. [Abstract]
- Nat Commun. 2025 Feb 19;16(1):1762. [Abstract]
- Nat Commun. 2024 Jul 26;15(1):6311. [Abstract]
- Acta Pharm Sin B. 2022 May;12(5):2358-2373. [Abstract]
- J Exp Clin Cancer Res. 2025 Oct 14;44(1):289. [Abstract]
- J Exp Clin Cancer Res. 2023 Jan 6;42(1):6. [Abstract]
- Adv Sci (Weinh). 2026 Jun 3:e75915. [Abstract]
- Adv Sci (Weinh). 2025 Mar;12(10):e2407942. [Abstract]
- Cell Rep Med. 2025 Aug 20:102310. [Abstract]
- Sci Adv. 2025 Oct 31;11(44):eadt3014. [Abstract]
- Cell Death Differ. 2026 Mar 11. [Abstract]
- Pharmacol Res. 2026 Apr 29:108214. [Abstract]
- Cell Death Dis. 2025 Apr 14;16(1):291. [Abstract]
- Int J Biol Sci. 2025 Mar 31;21(6):2707-2724. [Abstract]
- J Immunother Cancer. 2025 Mar 26;13(3):e008923. [Abstract]
- Int J Biol Sci. 2021 Oct 11;17(15):4207-4222. [Abstract]
- Oncogene. 2025 Sep 13. [Abstract]
- Oncogene. 2023 Aug;42(32):2456-2470. [Abstract]
- Cell Rep. 2024 May 18;43(6):114246. [Abstract]
- Brain Behav Immun. 2025 Jan:123:315-333. [Abstract]
- Anal Chem. 2020 Mar 17;92(6):4419-4426. [Abstract]
- Cancer Cell Int. 2023 Aug 11;23(1):164. [Abstract]
- Cancer Metab. 2025 Mar 31;13(1):16. [Abstract]
- Nutrients. 2018 Mar 15;10(3):353. [Abstract]
- Cancer Biol Ther. 2025 Dec;26(1):2450859. [Abstract]
- Int Immunopharmacol. 2021 Dec;101(Pt B):108225. [Abstract]
- J Lipid Res. 2024 Dec;65(12):100693. [Abstract]
- J Cell Sci. 2025 May 15;138(10):jcs263688. [Abstract]
- Prostaglandins Other Lipid Mediat. 2025 Jun:178:106988. [Abstract]
- Biomed Pharmacother. 2026 Feb:195:119070. [Abstract]
- University of Padua. 2025.
- Research Square Preprint. 2024 May 2.
- bioRxiv. 2023 Dec 1.
- McGill University. 2021 Aug, 30347448.
Customer Validation & Images
-
WB
-
Cell Proliferation/Viability Assay
-
Flow Cytometry
-
RT-PCR
-
WB
Actividad biológica
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| BXPC-3 | IC50 |
8.45 μM
Compound: Orlistat
|
Inhibition of survival of human BxPC3 cells after 10 to 14 days by crystal violet staining-based colony formation assay
Inhibition of survival of human BxPC3 cells after 10 to 14 days by crystal violet staining-based colony formation assay
|
[PMID: 25513712] |
| COS-7 | IC50 |
60 nM
Compound: THL
|
Inhibition of human recombinant DAGLalpha overexpressed in african green monkey COS7 cells
Inhibition of human recombinant DAGLalpha overexpressed in african green monkey COS7 cells
|
[PMID: 18657971] |
| COS-7 | IC50 |
60 nM
Compound: THL
|
Inhibition of human recombinant DAGLbeta overexpressed in african green monkey COS7 cells
Inhibition of human recombinant DAGLbeta overexpressed in african green monkey COS7 cells
|
[PMID: 18657971] |
| COS-7 | IC50 |
1 μM
Compound: 1, THL
|
Inhibition of human recombinant DAGL-alpha-mediated sn-1-[14C]oleoyl-2-arachidonoyl-glycerol hydrolysis to 2-AG overexpressed in african green monkey COS7 cell membrane by scintillation counting
Inhibition of human recombinant DAGL-alpha-mediated sn-1-[14C]oleoyl-2-arachidonoyl-glycerol hydrolysis to 2-AG overexpressed in african green monkey COS7 cell membrane by scintillation counting
|
[PMID: 18831576] |
| HEK293 | IC50 |
0.048 μM
Compound: THL
|
Inhibition of human ABHD6 containing pCMV6-AC-hABHD6 transfected into HEK293 cells
Inhibition of human ABHD6 containing pCMV6-AC-hABHD6 transfected into HEK293 cells
|
[PMID: 25752982] |
| HEK293 | IC50 |
0.19 μM
Compound: THL
|
Inhibition of human ABHD12 containing pCMV6-XL4-hABHD12 transfected into HEK293 cells
Inhibition of human ABHD12 containing pCMV6-XL4-hABHD12 transfected into HEK293 cells
|
[PMID: 25752982] |
| HEK293 | IC50 |
0.19 μM
Compound: THL, orlistat
|
Inhibition of human ABHD12 expressed in HEK293 cells pre-incubated for 10 mins before 2-AG substrate addition by HPLC method
Inhibition of human ABHD12 expressed in HEK293 cells pre-incubated for 10 mins before 2-AG substrate addition by HPLC method
|
[PMID: 26344596] |
| HEK-293T | IC50 |
>100 μM
Compound: THL
|
Inhibition of recombinant FAAH transfected in HEK293T cells by SDS-PAGE using rhodamine-tagged FP probe
Inhibition of recombinant FAAH transfected in HEK293T cells by SDS-PAGE using rhodamine-tagged FP probe
|
[PMID: 18657971] |
| HEK-293T | IC50 |
>100 μM
Compound: THL
|
Inhibition of recombinant KIAA1363 transfected in HEK293T cells by SDS-PAGE using rhodamine-tagged FP probe
Inhibition of recombinant KIAA1363 transfected in HEK293T cells by SDS-PAGE using rhodamine-tagged FP probe
|
[PMID: 18657971] |
| HEK-293T | IC50 |
0.03 μM
Compound: THL
|
Inhibition of recombinant BAT5 transfected in HEK293T cells by SDS-PAGE using rhodamine-tagged FP probe
Inhibition of recombinant BAT5 transfected in HEK293T cells by SDS-PAGE using rhodamine-tagged FP probe
|
[PMID: 18657971] |
| HEK-293T | IC50 |
0.05 μM
Compound: THL
|
Inhibition of recombinant PLA2g7 transfected in HEK293T cells by SDS-PAGE using rhodamine-tagged FP probe
Inhibition of recombinant PLA2g7 transfected in HEK293T cells by SDS-PAGE using rhodamine-tagged FP probe
|
[PMID: 18657971] |
| HEK-293T | IC50 |
0.08 μM
Compound: THL
|
Inhibition of recombinant ABHD12 transfected in HEK293T cells by SDS-PAGE using rhodamine-tagged FP probe
Inhibition of recombinant ABHD12 transfected in HEK293T cells by SDS-PAGE using rhodamine-tagged FP probe
|
[PMID: 18657971] |
| HEK-293T | IC50 |
10 nM
Compound: 3, THL
|
Inhibition of human DAGLalpha expressed in HEK293T cell membrane using [14C]SAG substrate in detergent free solution by FRET assay
Inhibition of human DAGLalpha expressed in HEK293T cell membrane using [14C]SAG substrate in detergent free solution by FRET assay
|
[PMID: 22738638] |
| HepG2 | EC50 |
28.2 μM
Compound: Orlistat
|
Activation of human PXR expressed in human HepG2 (DPX-2) cells assessed as induction of CYP3A4 after 24 hrs by luminescent analysis
Activation of human PXR expressed in human HepG2 (DPX-2) cells assessed as induction of CYP3A4 after 24 hrs by luminescent analysis
|
[PMID: 20966043] |
| MCF7 | IC50 |
>1 x 105 nM
Compound: 1; THL
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 29541373] |
| MDA-MB-231 | IC50 |
13 μM
Compound: 1; THL
|
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability
|
[PMID: 29541373] |
| MDA-MB-231 | IC50 |
>1 x 105 nM
Compound: 1; THL
|
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 29541373] |
| MDA-MB-435 | IC50 |
16.8 μM
Compound: orlistat
|
Cytotoxicity against human MDA-MB-435 cells after 48 hrs by Cell titer assay
Cytotoxicity against human MDA-MB-435 cells after 48 hrs by Cell titer assay
|
[PMID: 18710210] |
| NCI-H460 | IC50 |
>1 x 105 nM
Compound: 1; THL
|
Cytotoxicity against human H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 29541373] |
| PANC-1 | IC50 |
203 μM
Compound: Orlistat
|
Inhibition of FASN in human PANC1 cells assessed as inhibition of [14C]acetate incorporation preincubated for 4 hrs before [14C]acetate addition measured after 2 hrs by scintillation counting
Inhibition of FASN in human PANC1 cells assessed as inhibition of [14C]acetate incorporation preincubated for 4 hrs before [14C]acetate addition measured after 2 hrs by scintillation counting
|
[PMID: 25513712] |
Orlistat (40 μM; 2 days) does not affect MGMT levels in a human melanoma cell line, but downregulates the repair protein by 30-70% in human peripheral blood mononuclear cells, in two leukemia and two colon cancer cell lines. Orlistat does not alter noticeably MGMT mRNA expression[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:The human melanoma cell line M10, Peripheral blood mononuclear cells , The human Jurkat CD4+ T cell leukemia cell line, the human promyelocytic leukemia cell line HL-60, the epithelial colon cancer HCT116 cells,non adherent mononuclear cells (NAMNC)[1]
-
Concentration:2.5, 5, 10, 20, 40 μM for Jurkat cells; 20 and 40 μM for HCT116 cells; 40 μM for normal NAMNC, M10 melanoma, HL-60 promyelocytic leukemia, and HT-29 colon cancer cells
-
Incubation Time:2 days for Jurkat cells; 2 or 4 days for HCT116 cells; 2 days for NAMNC, M10 melanoma, HL-60 promyelocytic leukemia, HT-29 colon cancer
-
Result:Reduced by >50% the MGMT level at the concentration of 40 μM for Jurkat cells, whereas little or no effect was found when lower concentrations were used. Downregulation of MGMT expression is produced at 40 μM for HCT116 cells.
Provoked an ~50% reduction of MGMT level at 40 μM in normal NAMNC, and HL-60 promyelocytic leukemia, HT-29 colon cancer cells except for melanoma M10 cells that showed no downregulation of the protein.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Eighteen male rats of Sprague–Dawley strain aged between 8–10 weeks weighing 200-250 g[2]
-
Dosage:10 mg/kg/day
-
Administration:Orally; six weeks
-
Result:Treatment persistently restored the increased body weight, which was significantly observed at the ninth week until the end of the experimental period.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 96829-58-2
-
Appearance Solid
-
Peso molecular 495.73
-
Fòrmula C29H53NO5
-
Color White to off-white
-
SMILES
O=C1[C@@H](CCCCCC)[C@H](C[C@@H](OC([C@@H](N([H])C([H])=O)CC(C)C)=O)CCCCCCCCCCC)O1
-
Synonyms
Tetrahydrolipstatin; Ro-18-0647
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (34)
-
Journal Impact Factor
-
Most Recent
-
Cell Stem Cell
Injury-induced Clusterin+ cardiomyocytes suppress inflammation and promote regeneration in neonatal and adult hearts by reprogramming macrophages. [Abstract]2025 Dec 4;32(12):1849-1868.e15. PMID: 41205597 -
Nat Commun
Lipogenic enzyme FASN promotes mutant p53 accumulation and gain-of-function through palmitoylation. [Abstract]2025 Feb 19;16(1):1762. PMID: 39971971
Orlistat purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 19;16(1):1762. [Abstract]
Inhibition of FASN by Orlistat (50-100μM) reduced the protein levels of mutp53, but not wtp53, in different cells. Cells were treated with the small-molecule FASN inhibitor orlistat at the indicated concentrations for 24 h and then subjected to Western blot analysis.
Orlistat purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 19;16(1):1762. [Abstract]
Orlistat displayed a more pronounced inhibitory effect on AIG in p53R248W/- HCT116 and E1A/Ras-transformed p53R172H/R172H MEF cells compared with their corresponding p53+/+ or p53-/- cells. Cells were treated with or without Orlistat (50 or 100 µM) for 72 h for AIG assays.
-
Nat Commun
Cholesterol-rich lysosomes induced by respiratory syncytial virus promote viral replication by blocking autophagy flux. [Abstract]2024 Jul 26;15(1):6311. PMID: 39060258
Orlistat purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Jul 26;15(1):6311. [Abstract]
HEp-2 cells were either mock-infected or infected with RSV (MOI = 1) in the presence or absence of Orlistat (10 μM) for the indicated durations. The activity of LAL in HEp-2 cells 24 h after RSV infection was determined using flow cytometry (n = 3 independent experiments).
Orlistat purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Jul 26;15(1):6311. [Abstract]
HEp-2 cells were either mock-infected or infected with RSV (MOI = 1) in the presence or absence of Orlistat (10 μM) for the indicated durations. The mRNA level of LAL gene in HEp-2 cells 12 h or 24 h after RSV infection was determined using RT-PCR (n = 3 independent experiments).
Orlistat purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Jul 26;15(1):6311. [Abstract]
HEp-2 cells were either mock-infected or infected with RSV (MOI = 1) in the presence or absence of Orlistat (10 μM) for the indicated durations. Western blotting analysis of LAL in HEp-2 cells 12 h or 24 h after RSV infection (n = 3 independent experiments).
-
Acta Pharm Sin B
2022 May;12(5):2358-2373. PMID: 35646525 -
J Exp Clin Cancer Res
FASN inhibits ferroptosis in breast cancer via USP5 palmitoylation-dependent regulation of GPX4 deubiquitination. [Abstract]2025 Oct 14;44(1):289. PMID: 41088402 -
J Exp Clin Cancer Res
Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis. [Abstract]2023 Jan 6;42(1):6. PMID: 36604718 -
Adv Sci (Weinh)
2026 Jun 3:e75915. PMID: 42231807 -
Adv Sci (Weinh)
HACD2 Promotes Pancreatic Cancer Progression by Enhancing PKM2 Dissociation From PRKN in a Dehydratase-Independent Manner. [Abstract]2025 Mar;12(10):e2407942. PMID: 39836601 -
Cell Rep Med
An age-related decrease in leptin contributes to CD8+ T cell aging in the tumor microenvironment. [Abstract]2025 Aug 20:102310. PMID: 40858107 -
Sci Adv
Pharmacological targeting of RIG-I can selectively activate the integrated stress response. [Abstract]2025 Oct 31;11(44):eadt3014. PMID: 41160678 -
Cell Death Differ
Gut-derived hyodeoxycholate reprograms the spleen-eye immunometabolic axis to suppress autoimmune uveitis. [Abstract]2026 Mar 11. PMID: 41813862 -
Pharmacol Res
2026 Apr 29:108214. PMID: 42067003 -
Cell Death Dis
A targetable antioxidant defense mechanism to EZH2 inhibitors enhances tumor cell vulnerability to ferroptosis. [Abstract]2025 Apr 14;16(1):291. PMID: 40229247 -
Int J Biol Sci
NAMPT Impairs Vascular Permeability in Periodontitis by Influencing FASN-mediated Lipogenesis. [Abstract]2025 Mar 31;21(6):2707-2724. PMID: 40303304 -
J Immunother Cancer
2025 Mar 26;13(3):e008923. PMID: 40139835 -
Int J Biol Sci
Targeted Inhibition of LPL/FABP4/CPT1 fatty acid metabolic axis can effectively prevent the progression of nonalcoholic steatohepatitis to liver cancer. [Abstract]2021 Oct 11;17(15):4207-4222. PMID: 34803493 -
Oncogene
FOXA2 sensitizes endometrial carcinoma to progestin-mediated conservative therapy by triggering PR transcriptional activation. [Abstract]2025 Sep 13. PMID: 40946101 -
Oncogene
2023 Aug;42(32):2456-2470. PMID: 37400530 -
Cell Rep
Trophoblastic signals facilitate endometrial interferon response and lipid metabolism, ensuring normal decidualization. [Abstract]2024 May 18;43(6):114246. PMID: 38762885 -
Brain Behav Immun
Blockage of ATGL-mediated breakdown of lipid droplets in microglia alleviates neuroinflammatory and behavioural responses to lipopolysaccharides. [Abstract]2025 Jan:123:315-333. PMID: 39326768 -
Anal Chem
Molecular Imaging and In Situ Quantitative Profiling of Fatty Acid Synthase with a Chemical Probe. [Abstract]2020 Mar 17;92(6):4419-4426. PMID: 32053360 -
Cancer Cell Int
Enhancing prognostic accuracy in head and neck squamous cell carcinoma chemotherapy via a lipid metabolism-related clustered polygenic model. [Abstract]2023 Aug 11;23(1):164. PMID: 37568192 -
Cancer Metab
Unveiling the powerhouse: ASCL1-driven small cell lung cancer is characterized by higher numbers of mitochondria and enhanced oxidative phosphorylation. [Abstract]2025 Mar 31;13(1):16. PMID: 40165271 -
Nutrients
Glycycoumarin Sensitizes Liver Cancer Cells to ABT-737 by Targeting De Novo Lipogenesis and TOPK-Survivin Axis. [Abstract]2018 Mar 15;10(3):353. PMID: 29543705
Orlistat purchased from MedChemExpress. Usage Cited in: Nutrients. 2018 Mar 15;10(3):353. [Abstract]
Treatment with Orlistat (20-40 μM) leads to increased phospho-ACC without affecting the phosphorylation status of TOPK/survivin.
-
Cancer Biol Ther
NVP-2, in combination with Orlistat, represents a promising therapeutic strategy for acute myeloid leukemia. [Abstract]2025 Dec;26(1):2450859. PMID: 39800696 -
Int Immunopharmacol
AGT serves as a potential biomarker and drives tumor progression in colorectal carcinoma. [Abstract]2021 Dec;101(Pt B):108225. PMID: 34655849 -
J Lipid Res
2024 Dec;65(12):100693. PMID: 39505263 -
J Cell Sci
Tumor acidosis supports cancer cell lipid uptake via a rapid transporter-independent mechanism. [Abstract]2025 May 15;138(10):jcs263688. PMID: 40190115 -
Prostaglandins Other Lipid Mediat
E2F7 upregulates MCM4 and fatty acid metabolism to advance lung adenocarcinoma metastasis. [Abstract]2025 Jun:178:106988. PMID: 40158794 -
Biomed Pharmacother
Dual intestinal-hepatic modulation by phenolic acids improves metabolic-dysfunction associated steatohepatitis. [Abstract]2026 Feb:195:119070. PMID: 41610672 -
-
-
-
Solvente y solubilidad
DMSO : 100 mg/mL (201.72 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.04 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (5.04 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (280 KB)
-
SDS (537 KB)
- English - EN (537 KB)
- Français - FR (537 KB)
- Deutsch - DE (537 KB)
- Norwegian - NO (537 KB)
- Español - ES (537 KB)
- Swedish - SV (537 KB)
- Italian - IT (537 KB)
- Korean - KR (537 KB)
- Portuguese - PT (537 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Giorgia Cioccoloni, et al. Influence of fatty acid synthase inhibitor orlistat on the DNA repair enzyme O6-methylguanine-DNA methyltransferase in human normal or malignant cells in vitro. Int J Oncol. 2015 Aug;47(2):764-72. [Content Brief]
[2]. Zaidatul Akmal Othman, et al. Anti-Atherogenic Effects of Orlistat on Obesity-Induced Vascular Oxidative Stress Rat Model. Antioxidants (Basel). 2021 Feb 6;10(2):251. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.0172 mL | 10.0861 mL | 20.1723 mL | 50.4307 mL |
| 5 mM | 0.4034 mL | 2.0172 mL | 4.0345 mL | 10.0861 mL | |
| 10 mM | 0.2017 mL | 1.0086 mL | 2.0172 mL | 5.0431 mL | |
| 15 mM | 0.1345 mL | 0.6724 mL | 1.3448 mL | 3.3620 mL | |
| 20 mM | 0.1009 mL | 0.5043 mL | 1.0086 mL | 2.5215 mL | |
| 25 mM | 0.0807 mL | 0.4034 mL | 0.8069 mL | 2.0172 mL | |
| 30 mM | 0.0672 mL | 0.3362 mL | 0.6724 mL | 1.6810 mL | |
| 40 mM | 0.0504 mL | 0.2522 mL | 0.5043 mL | 1.2608 mL | |
| 50 mM | 0.0403 mL | 0.2017 mL | 0.4034 mL | 1.0086 mL | |
| 60 mM | 0.0336 mL | 0.1681 mL | 0.3362 mL | 0.8405 mL | |
| 80 mM | 0.0252 mL | 0.1261 mL | 0.2522 mL | 0.6304 mL | |
| 100 mM | 0.0202 mL | 0.1009 mL | 0.2017 mL | 0.5043 mL |
Orlistat Related Classifications
HY-B0218 Related Classifications
Powered by Bioz